Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges '.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Midcap 150 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon's wholly-owned subsidiary, Biocon Pharma Limited, has received U.S. FDA approval for its ANDA for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths. Everolimus is used to treat Tuberous Sclerosis Complex (TSC), including Subependymal Giant Cell Astrocytoma (SEGA) in patients aged 1 year and older, and as adjunctive therapy for TSC-associated partial-onset seizures in patients aged 2 years and older. The approval adds another product to Biocon's vertically integrated drug portfolio and enables entry into the U.S. generic market for this therapy.
This regulatory clearance allows Biocon to launch a generic version in the lucrative U.S. market, potentially boosting future revenue from its pharma segment. For shareholders, it strengthens the growth outlook for Biocon Pharma and reinforces the company's U.S. generics expansion strategy.